One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four strata based on entry serum bilirubin (<2 mg/dL vs. 2 mg/dL or greater) and liver histology (stages I, 1 1 vs. stages 111, IV-Ludwig criteria) were randomized within each stratum to ursodiol or placebo given in a s
A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid
✍ Scribed by Matti Vuoristo; Martti Fäarkkilä; Anna-Liisa Karvonen; Rauli Leino; Juhani Lehtola; Judit Mäkinen; Jorma Mattila; Claes Friman; Kari Seppälä; Juhani Tuominen; Tatu A. Miettinen
- Book ID
- 118882066
- Publisher
- Elsevier Science
- Year
- 1995
- Tongue
- English
- Weight
- 864 KB
- Volume
- 108
- Category
- Article
- ISSN
- 0016-5085
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The efficacy of colchicine combined with ursodeoxycholic acid (UDCA) and UDCA alone in the treatment of patients with nonadvanced primary biliary cirrhosis (PBC) was evaluated in a 2-year controlled study. Seventy-four patients with PBC who had been treated previously with UDCA (at least 8 months) b
A randomized placebo-controlled 2-year study was performed in 69 patients with primary biliary cirrhosis (PBC) on serum lipids during ursodeoxycholic acid (URSO) and colchicine treatments. In addition to serum bilirubin and alkaline phosphatase (AFOS), two variables considered to reflect liver funct
There is no doubt that further investigations of this phenomenon will be performed and published promptly. Until these questions are answered, we may appreciate the accuracy of Ogden Nash's old observation that "While candy is dandy, liquor is quicker!" 1.